BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31268158)

  • 1. Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map.
    Yen CC; Chen LT; Li CF; Chen SC; Chua WY; Lin YC; Yen CH; Chen YC; Yang MH; Chao Y; Fletcher JA
    Int J Oncol; 2019 Aug; 55(2):536-546. PubMed ID: 31268158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors.
    Zhang Y; Gu ML; Zhou XX; Ma H; Yao HP; Ji F
    Oncol Rep; 2014 Sep; 32(3):927-34. PubMed ID: 24970355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.
    Mu J; Sun X; Zhao Z; Sun H; Sun P
    Cell Death Dis; 2021 Oct; 12(11):962. PubMed ID: 34667163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
    Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
    Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low ETV1 mRNA expression is associated with recurrence in gastrointestinal stromal tumors.
    Sakamaki K; Funasaka K; Miyahara R; Furukawa K; Yamamura T; Ohno E; Nakamura M; Kawashima H; Hirooka Y; Fujishiro M; Goto H
    Sci Rep; 2020 Sep; 10(1):14767. PubMed ID: 32901065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
    Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
    Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
    Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
    Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
    [No Abstract]   [Full Text] [Related]  

  • 11. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
    Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
    Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of gastrointestinal stromal tumour.
    Kasireddy V; von Mehren M
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1.
    Birner P; Beer A; Vinatzer U; Stary S; Höftberger R; Nirtl N; Wrba F; Streubel B; Schoppmann SF
    Clin Cancer Res; 2012 Apr; 18(7):1879-87. PubMed ID: 22351694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Kondo T
    Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
    Jang BG; Lee HE; Kim WH
    Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.